

# Literaturverzeichnis

- [1] The world health report 2002: reducing risks, promoting healthy life. Technical report, World Health Organization, 2002.
- [2] Murray CJL and Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. *Global Burden of Disease and Injury Series*, I, 1996.
- [3] The world health report 2001: Mental health: new understanding, new hope. Technical report, World Health Organization, 2001.
- [4] The world health report 2003: shaping the future. Technical report, World Health Organization, 2003.
- [5] The africa malaria report 2003. Technical report, World Health Organization and UNICEF, 2002.
- [6] White NJ. Malaria. In G.C. Cook, editor, *Manson's Tropical Diseases*, pages 1087–1165. WB Saunders, London, 20th edition, 1996.
- [7] Kern P. Malaria. In R. Marre, T. Mertens, M. Trautmann, and E. Vanek, editors, *Klinische Infektiologie*, pages 641–649. Urban und Fischer Verlag, Muenchen, 1st edition, 2000.
- [8] Knobloch J. *Malaria - Grundlagen und klinische Praxis*. UNI-MED, Bremen, 1st edition, 2003.
- [9] Kretschmer H, Bienzle U, Klauss V, Kreamsner PG, and Leichsenring M. Malaria. In J. Knobloch, editor, *Tropen- und Reisemedizin*, pages 134–163. Gustav Fischer Verlag, 1996.
- [10] Miller LH, Baruch DI, Marsh K, and Doumbo OK. The pathogenic basis of malaria. *Nature*, 415(6872):673–9, 2002.
- [11] Weatherall DJ, Miller LH, Baruch DI, Marsh K, Doumbo OK, Casals-Pascual C, and Roberts DJ. Malaria and the red cell. *Hematology (Am Soc Hematol Educ Program)*, pages 35–57, 2002.
- [12] Imbert P, Gerardin P, Rogier C, Ka AS, Jouvencel P, Brousse V, and Guyon P. Severe falciparum malaria in children: a comparative study of 1990 and 2000 who criteria for clinical presentation, prognosis and intensive care in dakar, senegal. *Trans R Soc Trop Med Hyg*, 96(3):278–81, 2002.
- [13] Gilles HM. *Management of severe and complicated malaria: a practical handbook*. World Health Organisation, 2nd edition, 1991.

- [14] Severe and complicated malaria. world health organization, division of control of tropical diseases. *Trans R Soc Trop Med Hyg*, 84 Suppl 2:1–65, 1990.
- [15] Severe falciparum malaria. world health organization, communicable diseases cluster. *Trans R Soc Trop Med Hyg*, 94 Suppl 1:S1–90, 2000.
- [16] Dondorp AM, Angus BJ, Chotivanich K, Silamut K, Ruangveerayuth R, Hardeman MR, Kager PA, Vreeken J, and White NJ. Red blood cell deformability as a predictor of anemia in severe falciparum malaria. *Am J Trop Med Hyg*, 60(5):733–7, 1999.
- [17] Menendez C, Fleming AF, and Alonso PL. Malaria-related anaemia. *Parasitol Today*, 16(11):469–76, 2000.
- [18] Raventos-Suarez C, Kaul DK, Macaluso F, and Nagel RL. Membrane knobs are required for the microcirculatory obstruction induced by plasmodium falciparum-infected erythrocytes. *Proc Natl Acad Sci U S A*, 82(11):3829–33, 1985.
- [19] Sharma YD. Knobs, knob proteins and cytoadherence in falciparum malaria. *Int J Biochem*, 23(9):775–89, 1991.
- [20] Carlson J, Helmby H, Hill AV, Brewster D, Greenwood BM, and Wahlgren M. Human cerebral malaria: association with erythrocyte rosetting and lack of anti-rosetting antibodies. *Lancet*, 336(8729):1457–60, 1990.
- [21] Treutiger CJ, Hedlund I, Helmby H, Carlson J, Jepson A, Twumasi P, Kwiatkowski D, Greenwood BM, and Wahlgren M. Rosette formation in plasmodium falciparum isolates and anti-rosette activity of sera from gabians with cerebral or uncomplicated malaria. *Am J Trop Med Hyg*, 46(5):503–10, 1992.
- [22] Rowe A, Obeiro J, Newbold CI, and Marsh K. Plasmodium falciparum rosetting is associated with malaria severity in kenya. *Infect Immun*, 63(6):2323–6, 1995.
- [23] Trape JF, Rogier C, Konate L, Diagne N, Bouganali H, Canque B, Legros F, Badji A, Ndiaye G, Ndiaye P, and et al. The dielmo project: a longitudinal study of natural malaria infection and the mechanisms of protective immunity in a community living in a holoendemic area of senegal. *Am J Trop Med Hyg*, 51(2):123–37, 1994.
- [24] Smith T, Felger I, Tanner M, and Beck HP. Premunition in plasmodium falciparum infection: insights from the epidemiology of multiple infections. *Trans R Soc Trop Med Hyg*, 93 Suppl 1:59–64, 1999.
- [25] Haldane JBS. The rate of mutation of human genes. *Hereditas*, 35 (supplement):267–73, 1949.
- [26] Flint J, Harding RM, Boyce AJ, and Clegg JB. The population genetics of the haemoglobinopathies. *Baillieres Clin Haematol*, 11(1):1–51, 1998.
- [27] Pasvol G. The interaction between sickle haemoglobin and the malarial parasite plasmodium falciparum. *Trans R Soc Trop Med Hyg*, 74(6):701–5, 1980.
- [28] Shear HL, Grinberg L, Gilman J, Fabry ME, Stamatoyannopoulos G, Goldberg DE, and Nagel RL. Transgenic mice expressing human fetal globin are protected from malaria by a novel mechanism. *Blood*, 92(7):2520–6, 1998.

- [29] Luzzatto L, Nwachuku-Jarrett ES, and Reddy S. Increased sickling of parasitised erythrocytes as mechanism of resistance against malaria in the sickle-cell trait. *Lancet*, 1(7642):319–21, 1970.
- [30] Aidoo M, McElroy PD, Kolczak MS, Terlouw DJ, ter Kuile FO, Nahlen B, Lal AA, and Udhayakumar V. Tumor necrosis factor-alpha promoter variant 2 (tnf2) is associated with pre-term delivery, infant mortality, and malaria morbidity in western kenya: Asembo bay cohort project ix. *Genet Epidemiol*, 21(3):201–11, 2001.
- [31] McGuire W, Hill AV, Allsopp CE, Greenwood BM, and Kwiatkowski D. Variation in the tnf-alpha promoter region associated with susceptibility to cerebral malaria. *Nature*, 371(6497):508–10, 1994.
- [32] McGuire W, Knight JC, Hill AV, Allsopp CE, Greenwood BM, and Kwiatkowski D. Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. *J Infect Dis*, 179(1):287–90, 1999.
- [33] Koch O, Awomoyi A, Usen S, Jallow M, Richardson A, Hull J, Pinder M, Newport M, and Kwiatkowski D. Ifngr1 gene promoter polymorphisms and susceptibility to cerebral malaria. *J Infect Dis*, 185(11):1684–7, 2002.
- [34] Luty AJ, Kun JF, and Kremsner PG. Mannose-binding lectin plasma levels and gene polymorphisms in plasmodium falciparum malaria. *J Infect Dis*, 178(4):1221–4, 1998.
- [35] Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, Bennett S, Brewster D, McMichael AJ, and Greenwood BM. Common west african hla antigens are associated with protection from severe malaria. *Nature*, 352(6336):595–600, 1991.
- [36] Rockett KA, Awburn MM, Cowden WB, and Clark IA. Killing of plasmodium falciparum in vitro by nitric oxide derivatives. *Infect Immun*, 59(9):3280–3, 1991.
- [37] Fleming I and Busse R. No: the primary edrf. *J Mol Cell Cardiol*, 31(1):5–14, 1999.
- [38] Ignarro LJ, Buga GM, Wood KS, Byrns RE, and Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. *Proc Natl Acad Sci U S A*, 84(24):9265–9, 1987.
- [39] De Groote MA and Fang FC. No inhibitions: antimicrobial properties of nitric oxide. *Clin Infect Dis*, 21 Suppl 2:S162–5, 1995.
- [40] Fang FC. Perspectives series: host/pathogen interactions. mechanisms of nitric oxide-related antimicrobial activity. *J Clin Invest*, 99(12):2818–25, 1997.
- [41] Nathan C. Inducible nitric oxide synthase: what difference does it make? *J Clin Invest*, 100(10):2417–23, 1997.
- [42] Gyan B, Troye-Blomberg M, Perlmann P, and Bjorkman A. Human monocytes cultured with and without interferon-gamma inhibit plasmodium falciparum parasite growth in vitro via secretion of reactive nitrogen intermediates. *Parasite Immunol*, 16(7):371–5, 1994.
- [43] Mellouk S, Hoffman SL, Liu ZZ, de la Vega P, Billiar TR, and Nussler AK. Nitric oxide-mediated antiplasmodial activity in human and murine hepatocytes induced by gamma interferon and the parasite itself: enhancement by exogenous tetrahydrobiopterin. *Infect Immun*, 62(9):4043–6, 1994.

- [44] Nussler A, Drapier JC, Renia L, Pied S, Miltgen F, Gentilini M, and Mazier D. L-arginine-dependent destruction of intrahepatic malaria parasites in response to tumor necrosis factor and/or interleukin 6 stimulation. *Eur J Immunol*, 21(1):227–30, 1991.
- [45] Bogdan C. Nitric oxide and the immune response. *Nat Immunol*, 2(10):907–16, 2001.
- [46] Burgner D, Rockett K, and Kwiatkowski D. Nitric oxide and infectious diseases. *Arch Dis Child*, 81(2):185–8, 1999.
- [47] Hollenberg SM, Cunnion RE, and Zimmerberg J. Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to catecholamines in septic rats. *Am J Physiol*, 264(2 Pt 2):H660–3, 1993.
- [48] Lipton SA, Choi YB, Sucher NJ, and Chen HS. Neuroprotective versus neurodestructive effects of no-related species. *Biofactors*, 8(1-2):33–40, 1998.
- [49] Gyan B, Kurtzhals JA, Akanmori BD, Ofori M, Goka BQ, Hviid L, and Behr C. Elevated levels of nitric oxide and low levels of haptoglobin are associated with severe malarial anaemia in african children. *Acta Trop*, 83(2):133–40, 2002.
- [50] Kolb H and Kolb-Bachofen V. Nitric oxide in autoimmune disease: cytotoxic or regulatory mediator? *Immunol Today*, 19(12):556–61, 1998.
- [51] Mannick JB, Asano K, Izumi K, Kieff E, and Stamler JS. Nitric oxide produced by human b lymphocytes inhibits apoptosis and epstein-barr virus reactivation. *Cell*, 79(7):1137–46, 1994.
- [52] Clark IA, Rockett KA, and Cowden WB. Possible central role of nitric oxide in conditions clinically similar to cerebral malaria. *Lancet*, 340(8824):894–6, 1992.
- [53] Clark IA and Rockett KA. Nitric oxide and parasitic disease. *Adv Parasitol*, 37:1–56, 1996.
- [54] Al Yaman FM, Mokela D, Genton B, Rockett KA, Alpers MP, and Clark IA. Association between serum levels of reactive nitrogen intermediates and coma in children with cerebral malaria in papua new guinea. *Trans R Soc Trop Med Hyg*, 90(3):270–3, 1996.
- [55] al Yaman FM, Genton B, and Clark IA. The ratio of reactive nitrogen intermediates to tumour necrosis factor and clinical outcome of falciparum malaria disease. *Trans R Soc Trop Med Hyg*, 92(4):417–20, 1998.
- [56] Anstey NM, Weinberg JB, Hassanali MY, Mwaikambo ED, Manyenga D, Misukonis MA, Arnelle DR, Hollis D, McDonald MI, and Granger DL. Nitric oxide in tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. *J Exp Med*, 184(2):557–67, 1996.
- [57] Cot S, Ringwald P, Mulder B, Mialhes P, Yap-Yap J, Nussler AK, and Eling WM. Nitric oxide in cerebral malaria. *J Infect Dis*, 169(6):1417–8, 1994.
- [58] Chiwakata CB, Hemmer CJ, and Dietrich M. High levels of inducible nitric oxide synthase mrna are associated with increased monocyte counts in blood and have a beneficial role in plasmodium falciparum malaria. *Infect Immun*, 68(1):394–9, 2000.

- [59] Kremsner PG, Winkler S, Wildling E, Prada J, Bienzle U, Graninger W, and Nussler AK. High plasma levels of nitrogen oxides are associated with severe disease and correlate with rapid parasitological and clinical cure in plasmodium falciparum malaria. *Trans R Soc Trop Med Hyg*, 90(1):44–7, 1996.
- [60] MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, Stevens K, Xie QW, Sokol K, Hutchinson N, and et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. *Cell*, 81(4):641–50, 1995.
- [61] MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, and Nathan CF. Identification of nitric oxide synthase as a protective locus against tuberculosis. *Proc Natl Acad Sci U S A*, 94(10):5243–8, 1997.
- [62] Wei XQ, Charles IG, Smith A, Ure J, Feng GJ, Huang FP, Xu D, Muller W, Moncada S, and Liew FY. Altered immune responses in mice lacking inducible nitric oxide synthase. *Nature*, 375(6530):408–11, 1995.
- [63] Seguin MC, Klotz FW, Schneider I, Weir JP, Goodbary M, Slayter M, Raney JJ, Aniagolu JU, and Green SJ. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated plasmodium berghei infected mosquitoes: involvement of interferon gamma and cd8+ t cells. *J Exp Med*, 180(1):353–8, 1994.
- [64] Nathan C and Xie QW. Nitric oxide synthases: roles, tolls, and controls. *Cell*, 78(6):915–8, 1994.
- [65] Lowenstein CJ, Glatt CS, Bredt DS, and Snyder SH. Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. *Proc Natl Acad Sci U S A*, 89(15):6711–5, 1992.
- [66] Xu W, Charles IG, Liu L, Moncada S, and Emson P. Molecular cloning and structural organization of the human inducible nitric oxide synthase gene (nos2). *Biochem Biophys Res Commun*, 219(3):784–8, 1996.
- [67] de Vera ME, Shapiro RA, Nussler AK, Mudgett JS, Simmons RL, Jr. Morris SM, Billiar TR, and Geller DA. Transcriptional regulation of human inducible nitric oxide synthase (nos2) gene by cytokines: initial analysis of the human nos2 promoter. *Proc Natl Acad Sci U S A*, 93(3):1054–9, 1996.
- [68] Denis M. Human monocytes/macrophages: No or no no? *J Leukoc Biol*, 55(5):682–4, 1994.
- [69] Marks-Konczalik J, Chu SC, and Moss J. Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor kappaB-binding sites. *J Biol Chem*, 273(35):22201–8, 1998.
- [70] Taylor BS, de Vera ME, Ganster RW, Wang Q, Shapiro RA, Jr. Morris SM, Billiar TR, and Geller DA. Multiple nf-kappaB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. *J Biol Chem*, 273(24):15148–56, 1998.
- [71] Linn SC, Morelli PJ, Edry I, Cottongim SE, Szabo C, and Salzman AL. Transcriptional regulation of human inducible nitric oxide synthase gene in an intestinal epithelial cell line. *Am J Physiol*, 272(6 Pt 1):G1499–508, 1997.

- [72] Nicholson S, Bonecini-Almeida Mda G, Lapa e Silva JR, Nathan C, Xie QW, Mumford R, Weidner JR, Calaycay J, Geng J, Boechat N, Linhares C, Rom W, and Ho JL. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. *J Exp Med*, 183(5):2293–302, 1996.
- [73] Tsukahara Y, Morisaki T, Horita Y, Torisu M, and Tanaka M. Expression of inducible nitric oxide synthase in circulating neutrophils of the systemic inflammatory response syndrome and septic patients. *World J Surg*, 22(8):771–7, 1998.
- [74] Spitsin SV, Koprowski H, and Michaels FH. Characterization and functional analysis of the human inducible nitric oxide synthase gene promoter. *Mol Med*, 2(2):226–35, 1996.
- [75] Hobbs MR, Udhayakumar V, Levesque MC, Booth J, Roberts JM, Tkachuk AN, Pole A, Coon H, Kariuki S, Nahlen BL, Mwaikambo ED, Lal AL, Granger DL, Anstey NM, and Weinberg JB. A new nos2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in tanzanian and kenyan children. *Lancet*, 360(9344):1468–75, 2002.
- [76] Kun JF, Mordmuller B, Lell B, Lehman LG, Luckner D, and Kremsner PG. Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria. *Lancet*, 351(9098):265–6, 1998.
- [77] Xu W, Liu L, Emson PC, Harrington CR, and Charles IG. Evolution of a homopurine-homopyrimidine pentanucleotide repeat sequence upstream of the human inducible nitric oxide synthase gene. *Gene*, 204(1-2):165–70, 1997.
- [78] Burgner D, Xu W, Rockett K, Gravenor M, Charles IG, Hill AV, and Kwiatkowski D. Inducible nitric oxide synthase polymorphism and fatal cerebral malaria. *Lancet*, 352(9135):1193–4, 1998.
- [79] Levesque MC, Hobbs MR, Anstey NM, Vaughn TN, Chancellor JA, Pole A, Perkins DJ, Misukonis MA, Chanock SJ, Granger DL, and Weinberg JB. Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production, and disease severity in tanzanian children with malaria. *J Infect Dis*, 180(6):1994–2002, 1999.
- [80] Ohashi J, Naka I, Patarapotikul J, Hananantachai H, Looareesuwan S, and Tokunaga K. Significant association of longer forms of ccttt microsatellite repeat in the inducible nitric oxide synthase promoter with severe malaria in thailand. *J Infect Dis*, 186(4):578–81, 2002.
- [81] Xu W, Humphries S, Tomita M, Okuyama T, Matsuki M, Burgner D, Kwiatkowski D, Liu L, and Charles IG. Survey of the allelic frequency of a nos2a promoter microsatellite in human populations: assessment of the nos2a gene and predisposition to infectious disease. *Nitric Oxide*, 4(4):379–83, 2000.
- [82] Kun JF, Mordmuller B, Perkins DJ, May J, Mercereau-Puijalon O, Alpers M, Weinberg JB, and Kremsner PG. Nitric oxide synthase 2(lambarene) (g-954c), increased nitric oxide production, and protection against malaria. *J Infect Dis*, 184(3):330–6, 2001.
- [83] Warpeha KM, Xu W, Liu L, Charles IG, Patterson CC, Ah-Fat F, Harding S, Hart PM, Chakravarthy U, and Hughes AE. Genotyping and functional analysis of a polymorphic (ccttt)(n) repeat of nos2a in diabetic retinopathy. *Faseb J*, 13(13):1825–32, 1999.

- [84] Xu W, Liu L, Emson P, Harrington CR, McKeith IG, Perry RH, Morris CM, and Charles IG. The ccttt polymorphism in the nos2a gene is associated with dementia with lewy bodies. *Neuroreport*, 11(2):297–9, 2000.
- [85] Binka FN, Morris SS, Ross DA, Arthur P, and Aryeetey ME. Patterns of malaria morbidity and mortality in children in northern ghana. *Trans R Soc Trop Med Hyg*, 88(4):381–5, 1994.
- [86] Koram KA, Owusu-Agyei S, Utz G, Binka FN, Baird JK, Hoffman SL, and Nkrumah FK. Severe anemia in young children after high and low malaria transmission seasons in the kassena-nankana district of northern ghana. *Am J Trop Med Hyg*, 62(6):670–4, 2000.
- [87] Garnham PC. Malaria parasites and other haemosporidia. *Blackwell Scientific Publications*, page 130, 1966.
- [88] Molyneux ME, Taylor TE, Wirima JJ, and Borgstein A. Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose malawian children. *Q J Med*, 71(265):441–59, 1989.
- [89] Lodish HF, Berk AJ, Marsudaira P, Kaiser CA, Krieger M, Scott MP, Zipursky SL, and Darnell JE. *Molecular Cell Biology*. W. H. Freeman, New York, 5th edition, 2003.
- [90] Muelhardt C. *Der Experimentator: Molekularbiologie/Genomics*. Spektrum Akademischer Verlag, Heidelberg, Berlin, 3rd edition, 2002.
- [91] Hengen PN. Fidelity of dna polymerases for pcr. *Trends Biochem Sci*, 20(8):324–5, 1995.
- [92] Rust S, Funke H, and Assmann G. Mutagenically separated pcr (ms-pcr): a highly specific one step procedure for easy mutation detection. *Nucleic Acids Res*, 21(16):3623–9, 1993.
- [93] Sanger F, Nicklen S, and Coulson AR. Dna sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci U S A*, 74(12):5463–7, 1977.
- [94] Bortz J. *Statistik fuer Sozialwissenschaftler*. Springer, Heidelberg, Berlin, New York, 5th edition, 1999.
- [95] Trampisch HJ and Windeler J. *Medizinische Statistik*. Springer, Heidelberg, Berlin, New York, 2nd edition, 2000.
- [96] Mockenhaupt FP, Ehrhardt S, Burkhardt J, Bosomtwe SY, Laryea S, Anemana SD, Otchwemah RN, Cramer JP, Dietz E, Gellert S, and Bienzle U. Manifestation and outcome of severe malaria in children in northern ghana. *Am J Trop Med Hyg*, 71(2):167–72, 2004.
- [97] Feinstein AR. Experimental requirements and scientific principles in case-control studies. *J Chronic Dis*, 38(2):127–33, 1985.
- [98] Delley V, Bouvier P, Breslow N, Doumbo O, Sagara I, Diakite M, Mauris A, Dolo A, and Rougemont A. What does a single determination of malaria parasite density mean? a longitudinal survey in mali. *Trop Med Int Health*, 5(6):404–12, 2000.

- [99] 3rd Clendennen TE, Long GW, and Baird JK. Qbc and giemsa-stained thick blood films: diagnostic performance of laboratory technologists. *Trans R Soc Trop Med Hyg*, 89(2):183–4, 1995.
- [100] Kilian AH, Metzger WG, Mutschelknauss EJ, Kabagambe G, Langi P, Korte R, and von Sonnenburg F. Reliability of malaria microscopy in epidemiological studies: results of quality control. *Trop Med Int Health*, 5(1):3–8, 2000.
- [101] Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, Thaithong S, and Brown KN. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. *Mol Biochem Parasitol*, 61(2):315–20, 1993.
- [102] Burgner D, Usen S, Rockett K, Jallow M, Ackerman H, Cervino A, Pinder M, and Kwiatkowski DP. Nucleotide and haplotypic diversity of the nos2a promoter region and its relationship to cerebral malaria. *Hum Genet*, 112(4):379–86, 2003.
- [103] Mombo LE, Ntoumi F, Bisseye C, Ossari S, Lu CY, Nagel RL, and Krishnamoorthy R. Human genetic polymorphisms and asymptomatic plasmodium falciparum malaria in gabonese schoolchildren. *Am J Trop Med Hyg*, 68(2):186–90, 2003.
- [104] Boutlis CS, Hobbs MR, Marsh RL, Misukonis MA, Tkachuk AN, Lagog M, Booth J, Granger DL, Bockarie MJ, Mgone CS, Levesque MC, Weinberg JB, and Anstey NM. Inducible nitric oxide synthase (nos2) promoter ccttt repeat polymorphism: relationship to in vivo nitric oxide production/nos activity in an asymptomatic malaria-endemic population. *Am J Trop Med Hyg*, 69(6):569–73, 2003.
- [105] Oates JC, Levesque MC, Hobbs MR, Smith EG, Molano ID, Page GP, Hill BS, Weinberg JB, Cooper GS, and Gilkeson GS. Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in african-americans. *J Rheumatol*, 30(1):60–7, 2003.
- [106] Clark IA, Rockett KA, and Burgner D. Genes, nitric oxide and malaria in african children. *Trends Parasitol*, 19(8):335–7, 2003.
- [107] Burgner D, Rockett K, Ackerman H, Hull J, Usen S, Pinder M, and Kwiatkowski DP. Haplotypic relationship between snp and microsatellite markers at the nos2a locus in two populations. *Genes Immun*, 4(7):506–14, 2003.
- [108] Clark IA, Awburn MM, Whitten RO, Harper CG, Liomba NG, Molyneux ME, and Taylor TE. Tissue distribution of migration inhibitory factor and inducible nitric oxide synthase in falciparum malaria and sepsis in african children. *Malar J*, 2:6, 2003.
- [109] Cramer JP, Mockenhaupt FP, Ehrhardt S, Burkhardt J, Otchwemah RN, Dietz E, Gellert S, and Bienzle U. inos promoter variants and severe malaria in ghanaian children. *Trop Med Int Health*, 9(10):1074–80, 2004.